{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-002960","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.860846+00:00","generated_at":"2026-05-15T00:10:46.114644+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones","bullets":["BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.","Tiered royalties on net sales of navenibart in Europe range from 18% to 30%.","Navenibart Phase 3 in hereditary angioedema on track for US regulatory filing by end of 2027.","Agreement builds on prior 2025 deal for sale of European ORLADEYO business to Neopharmed Gentili."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-002960","json":"https://secwatch.observer/filing/0001171843-26-002960.json","markdown":"https://secwatch.observer/filing/0001171843-26-002960.md","text":"https://secwatch.observer/filing/0001171843-26-002960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/0001171843-26-002960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326002960/f8k_050426.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:10:46.114644+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}